<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:10pt Times New Roman, serif; }
 .font4 { font:13pt Times New Roman, serif; }
 .font5 { font:14pt Times New Roman, serif; }
 .font6 { font:19pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font6">J.P. Morgan</span></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p>
<p><a name="bookmark0"></a><span class="font5" style="font-weight:bold;"><a name="bookmark1"></a>SOE background with distinct advantages</span></p>
<p><span class="font4">We think Sinopharm’s SOE background offers distinct advantages</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Relative higher bargaining power with hospitals</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Easy access/secure local tender for pharmaceutics’ procurement</span></p></li>
<li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Lower financing cost - Sinopharm can borrow at a much lower rate; its one year note interest rate is around 3%, much lower than the base rate of 4.35%. The average financing cost is 5.2%. As in 1H16, Sinopharm has issued very short term notes and corporate bonds with an average interest rate of 2.5-3%.</span></p></li></ul>
<p><span class="font4">According to management, there is still room for further financing cost reduction, which is positive to Sinopharm’s future M&amp;A activities and development of new businesses.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">• &nbsp;&nbsp;&nbsp;Potential incentive plan for senior management with SOE reform: as one of the first few SOE companies to implement SOE mixed ownership reform, Sinopham submitted its application to the state council and may get approval soon.. Notably, Sinopharma released a share incentive schemes to incentivize key management's performance towards company’s long-term growth. The scheme will be effective for 10 years. It generally grants the participants with company shares based on reported 1) ROE and 2) net profit growth. The plan will increase management incentives, implying higher incentives and better performance ahead, in our view</span></p></li></ul>
<p><span class="font3">ii</span></p>
</body>
</html>